Mao Hu, Azadeh Shoaibi, Yuhui Feng, Patricia C Lloyd, Hui Lee Wong, Elizabeth R Smith, Kandace L Amend, Annemarie Kline, Daniel C Beachler, Joann F Gruber, Mahasweta Mitra, John D Seeger, Charlalynn Harris, Alex Secora, Joyce Obidi, Jing Wang, Jennifer Song, Cheryl N McMahill-Walraven, Christian Reich, Rowan McEvoy, Rose Do, Yoganand Chillarige, Robin Clifford, Danielle D Cooper, Richard A Forshee, Steven A Anderson
IMPORTANCE: Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials. OBJECTIVE: To conduct near-real-time monitoring of health outcomes after COVID-19 vaccination in the US pediatric population. DESIGN, SETTING, AND PARTICIPANTS: This cohort study evaluated 21 prespecified health outcomes after exposure before early 2023 to BNT162b2, mRNA-1273, or NVX-CoV2373 ancestral monovalent COVID-19 vaccines in children aged 6 months to 17 years by applying a near-real-time monitoring framework using health care data from 3 commercial claims databases in the US (Optum [through April 2023], Carelon Research [through March 2023], and CVS Health [through February 2023])...
April 1, 2024: JAMA Network Open